TROP2 ADC Development: Exploring the Datopotamab Deruxtecan Mechanism, Clinical Efficacy, & Future Directions
Time: 9:30 am
day: Day One AM
Details:
- Delving into the intricacies of Dato-DXd mechanism of action and the innovative approach in developing ADCs with the DXd linker-payload technology
- Examining the comprehensive late-stage clinical data for Dato-DXd, highlighting its clinical efficacy and safety profile
- Discussing the critical insights gained from the development of Dato-DXd, and outline the strategic next steps for its clinical application and further development
